UBS Group’s TransCode Therapeutics RNAZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.2K | Sell |
1,432
-7,994
| -85% | -$62.4K | ﹤0.01% | 7479 |
|
|
2025
Q1 | $131K | Buy |
9,426
+9,116
| +2,941% | +$126K | ﹤0.01% | 5580 |
|
|
2024
Q4 | $29.2K | Buy |
+310
| New | +$29.2K | ﹤0.01% | 6398 |
|
|
2024
Q3 | – | Sell |
-81
| Closed | -$75.3K | – | 8691 |
|
|
2024
Q2 | $75.3K | Buy |
+81
| New | +$75.3K | ﹤0.01% | 5233 |
|
|
2024
Q1 | – | Hold |
0
| – | -$1.3K | – | 8557 |
|
|
2023
Q4 | – | Sell |
-4
| Closed | -$73.7K | – | 7132 |
|
|
2023
Q3 | $73.7K | Buy |
+4
| New | +$73.7K | ﹤0.01% | 4923 |
|
|
2023
Q1 | – | Hold |
0
| – | -$777 | – | 8938 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 8873 |
|
|
2022
Q2 | – | Hold |
0
| – | -$11K | – | 9655 |
|
|
2022
Q1 | – | Hold |
0
| – | -$13K | – | 7262 |
|
|
2021
Q4 | – | Hold |
0
| – | -$16K | – | 7347 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 6289 |
|